Chidamide+venetoclax

Phase 2Small molecule

SShanghai Jiao Tong University School of Medicine

Chidamide+venetoclax is one of 16 small molecule programs targeting Acute Promyelocytic Leukemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Promyelocytic LeukemiaRecruiting

Acute Promyelocytic LeukemiaPhase 2

Recruiting

Competition

Competitive Landscape

15 competitors in Acute Promyelocytic Leukemia

#DrugCompanyPhaseTrials

Idamycin

Pfizer

Approved

9 2

Cytosar

Teva

Approved

8 3

Trisenox

CCephalon

Approved

20 4

Jakafi

Incyte

Approved

1 5

Scemblix

Istodax

Novantrone

3 8

Cerubidine

HHikma Pharmaceuticals LLC

Approved

1 9

Novantrone

Pfizer

Phase 3

3 10

Venclexta

AbbVie

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acute Promyelocytic Leukemia1 trial

Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia

Recruiting·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT05881265·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Chidamide+venetoclax. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Chidamide+venetoclax compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Chidamide+venetoclax. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Jiao Tong University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShanghai Jiao Tong University School of Medicine

Chidamide+venetoclax

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acute Promyelocytic Leukemia1 trial

References

Drug Info

Quick Facts

Related News